Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VADIS: Nelipepimut-S in DCIS
NCT02636582Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Jul 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of nelipepimut-S in ductal carcinoma in situ (DCIS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Mean Percent of Nelipepimut-S-specific Cytotoxic T Lymphocyte Response. Started Jun 2016; status: completed.
02
Drugs
nelipepimut-S
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02636582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636582.